Boston Scientific
From Wikipedia, the free encyclopedia
| Boston Scientific | |
|---|---|
 |
|
| Type | Public (NYSE: BSX) |
| Founded | 1979 |
| Headquarters | Natick, Massachusetts |
| Key people | John Abele, Founder & Director Peter Nicholas, Founder & Chairman James Tobin, CEO Paul LaViolette, COO |
| Industry | Medical Instruments & Supplies |
| Revenue | ▲$7.821 Billion USD (2006) |
| Net income | (▼$3.557 Billion) USD (2006) |
| Employees | 28,600 (2007) |
| Website | www.bostonscientific.com |
The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Boston Scientific is well known for the development of the Taxus Stent, a drug-coated stent which is used to open clogged arteries. This product was at the center of a claim of patent infringement on the part of Boston Scientific, which was found liable for $431 million in damages.[1]
Boston Scientific's main competitors are Johnson & Johnson and Medtronic. The company recently acquired longtime competitor Guidant for approximately $27 billion. The former Guidant was split between BSC and Abbott Laboratories. [2] [3]
[edit] Notes
- ^ "Boston Scientific Loses Patent Trial", New York Times, February 13, 2008. Retrieved on 2008-02-13.
- ^ "Guidant battle ends in favor of Boston Scientific", Associated Press, January 25, 2006. Retrieved on 2008-02-11.
- ^ Boston Scientific Completes Combination with Guidant (April 21, 2006). Retrieved on 2008-02-11. Boston Scientific's press release on the acquisition.
